Leaders of China, South Korea to Discuss North Korea Nuclear Threat

Global Security Newswire Staff
See more stories about...
Global Security Newswire Staff
July 1, 2014, 10:31 a.m.

The lead­ers of South Korea and China are slated to hold a sum­mit this week that will closely con­sider North Korea’s nuc­le­ar weapons work.

Chinese Pres­id­ent Xi Jin­ping is sched­uled to travel to South Korea to meet with South Korean Pres­id­ent Park Geun-hye for their fifth meet­ing so far this year. The vis­it comes as Xi has yet to sit down with North Korean ruler Kim Jong Un, Re­u­ters re­ports. In­ter­na­tion­al ob­serv­ers are ex­pec­ted to watch if Xi gives any in­dic­a­tion of his gov­ern­ment’s per­ceived frus­tra­tion with Py­ongy­ang’s con­tin­ued pro­voc­at­ive tac­tics and pur­suit of a de­liv­er­able nuc­le­ar weapon.

China has long been North Korea’s biggest for­eign ally and chief eco­nom­ic be­ne­fact­or. However, the bel­li­ger­ent ac­tions of the Kim re­gime in re­cent years —  in­clud­ing the ap­par­ent test-fir­ing in 2012 of a long-range bal­list­ic mis­sile, a 2013 nuc­le­ar test and re­peated threats earli­er this spring of an­oth­er atom­ic det­on­a­tion, as well as the high-pro­file ex­e­cu­tion last winter of Kim’s uncle — are thought to have pushed Beijing to the lim­its of its pa­tience.

Xi and Park “are ex­pec­ted to spend con­sid­er­able time dis­cuss­ing the North Korean nuc­le­ar and the Korean pen­in­sula is­sues in depth, and we be­lieve the at­mo­sphere will be ap­pro­pri­ately re­flec­ted in a joint doc­u­ment,” South Korean For­eign Min­is­ter Yun By­ung-se told law­makers on Monday. Chinese Vice For­eign Min­is­ter Liu Zhen­min on Tues­day said the North Korean nuc­le­ar im­passe would be an “im­port­ant top­ic” for dis­cus­sion dur­ing the Seoul-Beijing meet­ing.

Both China and South Korea are par­ti­cipants in a frozen six-na­tion pro­cess aimed at per­man­ently end­ing North Korea’s nuc­le­ar work. While Seoul wants Py­ongy­ang to first provide a con­crete ges­ture of its com­mit­ment to de­nuc­lear­iz­a­tion be­fore the ne­go­ti­ations are re­sumed, Beijing does not be­lieve there should be any pre­con­di­tions be­fore talks con­tin­ue.

MOST READ
What We're Following See More »
BUT HE’S NOT ADVOCATING FOR IT
Grassley Open to Lame Duck Hearings on Garland
14 hours ago
THE LATEST

Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.

Source:
DOWN FROM POST-CONVENTION NUMBERS
Monmouth Has Clinton Up Seven
18 hours ago
THE LATEST

In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.

Source:
DEBATE PREP
Clinton Advisers Talking to Psychologists, Trump Ghostwriter
19 hours ago
THE LATEST

“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”

EPI-PEN PRICES
House Committee Investigating Mylan
21 hours ago
THE LATEST

The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.

Source:
×